



VITB12 DEFICIENCY IN METFORMIN USERS AND RELATION TO RENAL FUNCTIONS IN TYPE2DM

Mo'men sayed Taha¹, Amr Mahmoud Abdel Wahab¹, Mohammed Omer Abdeleziz¹, Ahmed Abdelfadil Saudi², Mohamed Mamdouh Mohamed Ismael³

Article History: Received: 10.04.2023

Revised: 20.06.2023

Accepted: 30.06.2023

Abstract:

Vitamin B12 deficiency is common among patients with type 2 diabetes mellitus (T2D). Although metformin therapy is the principal factor, advanced age with types DM, nutritional deficiency, and malabsorption are other contributing factors (1)

The proposed mechanisms for deficiency include impairment of calcium-dependent absorption from the gut, alteration in small bowel motility resulting in bacterial overgrowth, and a reduction in intrinsic factor levels (2). Several studies have reported that metformin-induced vitamin B12 deficiency contributes to the high prevalence and/or worsening of existing peripheral neuropathy in patients with T2D (3).

1 Internal Medicine Department, Faculty of Medicine, Minya University

2 Clinical Pathology Department, Faculty of Medicine, Minya University

3 Neuropsychiatry Department, Faculty of Medicine, Minya University

DOI:10.48047/ecb/2023.12.si12.176

Introduction

Vitamin B12 deficiency is common among patients with type 2 diabetes mellitus (T2D). Although metformin therapy is the principal factor, advanced age with types DM, nutritional deficiency, and malabsorption are other contributing factors (1)

The proposed mechanisms for deficiency include impairment of calcium-dependent absorption from the gut, alteration in small bowel motility resulting in bacterial overgrowth, and a reduction in intrinsic factor levels (2). Several studies have reported that metformin-induced vitamin B12 deficiency contributes to the high prevalence and/or worsening of existing peripheral neuropathy in patients with T2D (3).

Several studies have investigated the individual effects of dose and duration of metformin therapy on vitamin B12 levels. The reported results are inconsistent with some studies reporting an association with the dose but not the duration (4) and other studies reporting an association only for the duration (5). A few studies did not find an association with either the dose or the duration (6) and low prevalence of vitamin B12 deficiency

Physiological roles of vitamin B12

Vitamin B12 exerts its physiological effects through mediating two principal enzymatic pathways i.e. the methylation process of homocysteine to methionine and the conversion of methylmalonyl coenzyme A (CoA) to succinyl-CoA. Vitamin B12 as a co-factor facilitates the methylation of homocysteine to methionine which is later activated into S-adenosyl-methionine that donates its methyl group to methyl

acceptors such as myelin, neurotransmitters and membrane phospholipids.(7)

Metabolically significant vitamin B12 deficiency hence will result in disruption of the methylation process and accumulation of intracellular and serum homocysteine. Hyperhomocysteinemia has been shown to have potentially toxic effects on neurones and the vascular endothelium. This reaction is also essential in the conversion of dietary folate (methyl-tetrahydrofolate) to its active metabolic form, tetrahydrofolate. In another essential enzymatic pathway, vitamin B12 as a co-factor mediates the conversion of methylmalonyl coenzyme A (CoA) to succinyl-CoA. In the presence of vitamin B12 deficiency, this conversion pathway is diminished and an increase in the serum methylmalonic acid (MMA) ensues. This is followed by defective fatty acid synthesis of the neuronal membranes [3]. Vitamin B12 is also essential in the synthesis of monoamines or neurotransmitters like serotonin and dopamine [4]. This synthesis is impaired with vitamin B12 deficiency.

All the above collectively explain the resultant neuro-cognitive or psychiatric manifestations that accompany vitamin B12 deficiency. Axonal demyelination, degeneration and later death are the hallmark of vitamin B12 deficiency induced neuronal damage that manifests as severe peripheral or autonomic neuropathy, sub acute combined degeneration of the spinal cord, delirium and dementia [3,5]. Compelling evidence demonstrates that hyperhomocysteinemia is also associated with an increased risk of cardiovascular events due to its cellular and vasculo-toxic effects [6-8].

References

- 1-Kibirige D, Mwebaze R (2013) Vitamin B12 deficiency among patients with diabetes mellitus: is routine screening and supplementation justified? *J Diabetes Metab Disord* 12(1):17.
- 2-Ahmed MA, Muntingh G, Rheeder P (2016) Vitamin B12 deficiency in metformin-treated type-2 diabetes patients, prevalence and association with peripheral neuropathy. *BMC Pharmacol Toxicol* 17(1):44.
3. Reinstatler L, Qi YP, Williamson RS, Garn JV, Oakley GP (2012) Association of biochemical B12 deficiency with metformin therapy and vitamin B12 supplements: the National Health and Nutrition Examination Survey, 1999–2006. *Diabetes Care* 35(2):327–333.
4. Alvarez M, Sierra OR, Saavedra G, Moreno S (2019) Vitamin B12 deficiency and diabetic neuropathy in patients taking metformin: a cross-sectional study. *Endocr Connect* 8(10):1324–1329.
5. De Jager J, Kooy A, Lehert P, Wulffelé MG, Van der Kolk J, Bets D, Verburg J, Donker AJ, Stehouwer CD (2010) Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo-controlled trial. *BMJ* 340:c2181.
6. Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, Bray GA, Schade DS, Tempresa MG, White NH, Crandall JP (2016) Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. *J Clin Endocrinol Metab* 101(4):1754–1761.
7. Pierce SA, Chung AH, Black KK (2012) Evaluation of vitamin B12 monitoring in a veteran population on long-term, high-dose metformin therapy. *Ann Pharmacother* 46(11):1470–1476.
8. Qureshi SA, Ainsworth A, Winocour PH (2011) Metformin therapy and assessment for vitamin B12 deficiency: is it necessary? *Pract. Diabetes* 28(7):302–304.